• 11/22/2023

    PAION AG CHANGES FROM PRIME STANDARD TO GENERAL STANDARD

  • 11/21/2023

    PAION AG SIGNS STRATEGIC COOPERATION AGREEMENT WITH YICHANG HUMANWELL

  • 10/31/2023

    PAION AG HAS FILED FOR THE OPENING OF INSOLVENCY PROCEEDINGS - PRELIMINARY INSOLVENCY ADMINISTRATOR APPOINTED

  • 10/20/2023

    PAION AG to issue approximately 4.8 million shares at EUR 1.90 per share in capital increase with subscription rights

  • 10/13/2023

    Press release: PAION AG announces fully underwritten rights issue with target gross proceeds of EUR 10 million

  • 09/28/2023

    PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE MUNDIPHARMA IN JAPAN

  • 08/31/2023

    PAION receives UK MHRA approval of Byfavo® (remimazolam) for the induction and maintenance of general anesthesia in adults

  • 08/30/2023

    PAION AG reports financial results for the First Half-Year 2023

  • 08/22/2023

    PAION launches Byfavo® (remimazolam) in the first European country for General Anesthesia

  • 07/17/2023

    PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO IN GENERAL ANESTHESIA IN THE PHILIPPINES

  • 07/12/2023

     PAION AG SUCCESSFULLY HOLDS ITS ANNUAL GENERAL MEETING 2023

  • 05/25/2023

    ​​​​​​​PAION IS HOSTING A SPONSORED BYFAVO® SYMPOSIUM AT  EUROANAESTHESIA 2023 IN GLASGOW

  • 05/17/2023

    PAION AG publishes GROUP QUARTERLY STATEMENT for the first quarter of 2023

  • 04/25/2023

    POSTPONEMENT OF PUBLICATION OF THE ANNUAL AND CONSOLIDATED FINANCIAL STATEMENTS 2022

  • 03/31/2023

    PAION AG implements resolved capital reduction

  • 03/30/2023

    PAION AG reports on fiscal year 2022

  • 03/16/2023

    PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS

  • 01/25/2023

    PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing

  • 01/19/2023

    ​​​​​​​PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL